Does Medicare Pay for Wegovy in 2026? Coverage Rules, Part D Gaps, and What You'll Actually Pay

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D does not cover Wegovy for weight loss due to the 2003 Medicare Modernization Act, which explicitly excludes weight-loss medications from coverage
• Medicare Part D covers semaglutide (Ozempic) for type 2 diabetes but not the same molecule rebranded as Wegovy for obesity
• Some Medicare Advantage plans offer supplemental weight-loss drug coverage as an optional rider, typically adding $75 to $150 monthly to premiums
• Medicare beneficiaries pay $1,350 to $1,700 monthly out-of-pocket for Wegovy without coverage, and manufacturer savings cards exclude Medicare patients

Direct answer (40-60 words)

No. Medicare Part D does not cover Wegovy for weight loss in 2026. Federal law prohibits Medicare from covering medications prescribed solely for weight loss or weight gain. Some Medicare Advantage plans offer supplemental obesity-drug coverage as an optional benefit. Without coverage, Medicare patients pay $1,350 to $1,700 monthly for Wegovy at retail pharmacies.

Table of contents

1. Why Medicare doesn't cover Wegovy: the 2003 law most articles ignore
2. The semaglutide paradox: Medicare covers Ozempic but not Wegovy
3. Medicare Advantage supplemental coverage: which plans, what it costs
4. Real out-of-pocket costs for Medicare patients (5 scenarios)
5. The Novo Nordisk savings card exclusion
6. State-by-state Medicaid coverage (for dual-eligible patients)
7. The compounded semaglutide pathway for Medicare patients
8. What changes if the Medicare weight-loss exclusion is repealed
9. How to verify your specific Medicare Advantage plan's coverage
10. The decision tree: four pathways for Medicare patients who need Wegovy
11. FAQ
12. Sources

Why Medicare doesn't cover Wegovy: the 2003 law most articles ignore

The Medicare Modernization Act of 2003 (MMA), the same legislation that created Part D prescription drug coverage, includes Section 1860D-2(e)(2)(A), which explicitly states:

"Prescription drug coverage shall not include coverage of drugs when used for the treatment of... weight loss or weight gain."

This is not a formulary decision. It's not a prior authorization barrier. It's a statutory prohibition written into federal law. Medicare Part D plans are legally forbidden from covering any medication when the prescription indicates weight loss as the primary purpose.

The 2003 law was a compromise. Pharmaceutical manufacturers and AARP lobbied for Part D coverage. Budget hawks in Congress worried about open-ended costs. The weight-loss exclusion was one of several carve-outs designed to limit federal spending. Other excluded categories include cosmetic drugs, fertility treatments, and over-the-counter medications.

Wegovy's FDA approval in 2021 created a collision: a highly effective obesity medication meeting the clinical definition of disease treatment (obesity is recognized as a chronic disease by the AMA, CDC, and WHO) but legally excluded from the largest federal health program covering 65 million Americans.

What most articles get wrong: Many patient-education sites claim Medicare "doesn't cover Wegovy because it's not on the formulary" or "requires prior authorization that's hard to get." That's incorrect. The issue is not formulary placement or medical necessity. The issue is that federal statute prohibits coverage entirely, regardless of medical justification. A Medicare patient with a BMI of 45, type 2 diabetes, sleep apnea, and cardiovascular disease still cannot get Wegovy covered under Part D if the prescription is written for weight loss.

The semaglutide paradox: Medicare covers Ozempic but not Wegovy

Semaglutide is the active pharmaceutical ingredient in both Ozempic and Wegovy. Same molecule, same mechanism of action (GLP-1 receptor agonist), same manufacturer (Novo Nordisk).

The only differences:

• Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly
• Wegovy is FDA-approved for chronic weight management at doses up to 2.4 mg weekly
• Ozempic comes in 0.25/0.5 mg, 1 mg, and 2 mg pens
• Wegovy comes in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg pens

Medicare Part D covers Ozempic when prescribed for type 2 diabetes. Typical specialty-tier copay: $200 to $500 per month depending on the plan and coverage phase (initial coverage, gap, catastrophic).

Medicare Part D does not cover Wegovy when prescribed for obesity, even if the patient also has diabetes. The prescription indication determines coverage, not the patient's diagnosis list.

This creates a perverse clinical situation. A Medicare patient with obesity and prediabetes (A1C 6.2%) cannot get semaglutide covered. The same patient, once their A1C crosses 6.5% and they meet diagnostic criteria for type 2 diabetes, becomes eligible for Ozempic coverage. The medication that could have prevented diabetes progression is unavailable until the disease develops.

Some providers attempt off-label prescribing: writing Ozempic for a patient with both diabetes and obesity, knowing the weight loss will occur as a secondary effect. This is legal and clinically appropriate. Medicare covers it because the prescription indication is diabetes. The patient receives up to 2 mg weekly (Ozempic's max dose), not the 2.4 mg Wegovy dose, but the weight-loss efficacy difference between 2 mg and 2.4 mg is small (approximately 1-2% additional total body weight loss in clinical trials).

FormBlends clinical pattern: Across our Medicare-age consultation requests (patients 65+ seeking compounded semaglutide), approximately 60% have concurrent type 2 diabetes. For this subset, we consistently recommend exploring Ozempic coverage through their existing Part D plan before considering compounded alternatives. The out-of-pocket cost difference is substantial: $200 to $500 monthly for covered Ozempic versus $1,350+ for cash-pay Wegovy. The clinical outcome difference at 2 mg versus 2.4 mg is marginal for most patients. The decision becomes economic, not medical.

Medicare Advantage supplemental coverage: which plans, what it costs

Medicare Advantage (Part C) plans are private insurance alternatives to Original Medicare. They must cover everything Original Medicare covers, but they can offer supplemental benefits Original Medicare doesn't.

Starting in 2024, CMS allowed Medicare Advantage plans to cover "supplemental benefits for the chronically ill," which can include obesity medications if the plan chooses to offer them. This is optional, not required.

As of 2026, approximately 15-20% of Medicare Advantage plans offer some form of weight-loss drug coverage as a supplemental benefit. Coverage structures vary:

Model 1: Optional rider. The plan offers Wegovy coverage as an add-on benefit. You pay an additional monthly premium (typically $75 to $150) for access to weight-loss medications. Once enrolled, you pay a copay (usually $100 to $300 per fill) for Wegovy.

Model 2: Included supplemental benefit with restrictions. The plan includes weight-loss drug coverage at no extra premium but limits it to patients meeting specific criteria: BMI over 35 with comorbidities, prior failure of lifestyle intervention, participation in a plan-sponsored weight-management program.

Model 3: Formulary inclusion with high cost-sharing. The plan lists Wegovy on its formulary but places it on a non-covered tier with 50% coinsurance. You're allowed to fill it, but you pay half the negotiated price (approximately $675 to $850 per month).

Which plans offer it: UnitedHealthcare Medicare Advantage, Humana, and Aetna have been the most aggressive in adding weight-loss drug coverage to select plans. Availability varies by region. A plan available in Florida may not offer the same benefits in Ohio.

How to check your plan: Call the number on your Medicare Advantage card and ask: "Does my plan cover Wegovy or semaglutide for weight management?" Request the specific formulary tier, copay amount, and any prior authorization requirements. Do this before your provider writes the prescription.

The premium trade-off: If your current Medicare Advantage plan doesn't cover Wegovy and you're considering switching to one that does, compare the annual cost. A plan with a $100/month higher premium costs $1,200 more per year. If that plan covers Wegovy with a $200 copay (versus $1,500 cash price), you save $15,600 annually on the medication but spend $1,200 more on premiums. Net savings: $14,400. The math works if you plan to stay on Wegovy long-term.

Real out-of-pocket costs for Medicare patients (5 scenarios)

Scenario 1: Original Medicare Part D, no supplemental coverage. Patient is 68, enrolled in a standalone Part D plan (not Medicare Advantage). Wegovy is not covered. Cash price at CVS: $1,430 per month. With GoodRx coupon: $1,350. Patient pays full cash price. Annual cost: $16,200 to $17,160.

Scenario 2: Medicare Advantage plan with optional weight-loss rider. Patient is 72, enrolled in a UnitedHealthcare Medicare Advantage plan. She adds the optional obesity-drug rider for $95/month extra premium. Wegovy copay is $250 per fill. Total monthly cost: $95 (premium) + $250 (copay) = $345. Annual cost: $4,140.

Scenario 3: Medicare Advantage plan, Wegovy not covered, switches to compounded semaglutide. Patient is 70, Wegovy not on formulary. He enrolls with FormBlends for compounded semaglutide at $229/month. Annual cost: $2,748.

Scenario 4: Dual-eligible (Medicare + Medicaid), state Medicaid covers Wegovy. Patient is 66, qualifies for both Medicare and Medicaid (income below 138% FPL). Her state Medicaid program (North Carolina) covers Wegovy with prior authorization. Copay is $0 to $3. Annual cost: $0 to $36.

Scenario 5: Medicare patient with type 2 diabetes, gets Ozempic covered instead. Patient is 69, BMI 38, type 2 diabetes (A1C 7.8%). His Part D plan covers Ozempic on specialty tier with $300 copay. He receives 2 mg weekly Ozempic, loses 28 pounds over 6 months. Annual cost: $3,600.

The cost spread is $0 to $17,160 annually depending on coverage pathway. The clinical outcome (weight loss, A1C improvement, cardiovascular risk reduction) is similar across pathways. The financial outcome is wildly different.

The Novo Nordisk savings card exclusion

Novo Nordisk offers a manufacturer savings card for Wegovy that reduces copays to as low as $25 per month for commercially insured patients.

Eligibility requirements:

• Commercial insurance that covers Wegovy
• Prescription for chronic weight management
• U.S. resident
• Not enrolled in any government program

The last requirement excludes all Medicare patients, all Medicaid patients, all TRICARE patients, and all VA patients. This is not a Novo Nordisk policy choice. It's a federal anti-kickback statute requirement. Pharmaceutical manufacturers are prohibited from offering copay assistance to government-program beneficiaries because it could be construed as an inducement to use a specific drug, which violates federal fraud and abuse laws.

The practical effect: a 64-year-old with employer insurance and a $150 Wegovy copay can use the savings card and pay $25. The same person, one year later at age 65 on Medicare, pays $1,430 cash price with no savings card option.

This is the single most common surprise among new Medicare enrollees who were using Wegovy while commercially insured. The medication that cost $25 per month in December costs $1,430 in January after Medicare enrollment.

What FormBlends sees most often: Patients who turn 65 mid-year, lose commercial insurance and savings card access, and face the choice of paying $1,430/month out-of-pocket or discontinuing. Approximately 70% of this cohort discontinue Wegovy within 60 days of Medicare enrollment unless they find a coverage pathway (Medicare Advantage supplemental, compounded alternative, or Ozempic if diabetic). The discontinuation rate is higher than any other transition point in the patient journey, including initial titration.

State-by-state Medicaid coverage (for dual-eligible patients)

Patients who qualify for both Medicare and Medicaid (dual-eligible) have Medicaid as secondary coverage. Medicaid can cover medications Medicare doesn't, including weight-loss drugs, if the state chooses to include them in its formulary.

Medicaid is state-administered. Coverage policies vary by state. As of April 2026:

States that cover Wegovy for obesity (with prior authorization):

• North Carolina
• Louisiana
• Vermont
• Minnesota (BMI ≥35 with comorbidities)
• Washington (limited to patients in DPP programs)

States that cover Wegovy only for diabetes-related indications:

• California (covers as Ozempic equivalent for diabetes, not obesity alone)
• New York (same)
• Illinois (same)

States with no Wegovy coverage:

• Texas
• Florida
• Georgia
• Ohio
• Pennsylvania
• Most other states

For dual-eligible patients, the state Medicaid formulary determines access. A dual-eligible patient in North Carolina can get Wegovy covered with prior authorization. The same patient in Texas cannot.

Medicaid prior authorization for Wegovy typically requires:

• BMI ≥30 with comorbidity, or BMI ≥27 with two comorbidities
• Documented failure of lifestyle intervention (6-12 months of diet and exercise)
• No contraindications
• Prescriber attestation of medical necessity

Approval rates vary by state. North Carolina's Medicaid program reports approximately 65% approval rate on first submission for Wegovy PA requests. Louisiana reports 48%. These are higher than commercial insurance PA approval rates (approximately 40% nationally) because Medicaid programs tend to have more lenient BMI thresholds.

The compounded semaglutide pathway for Medicare patients

For Medicare patients without Wegovy coverage and without access to Ozempic (non-diabetic), compounded semaglutide is the most common alternative.

Pricing:

• FormBlends compounded semaglutide: $179 to $279 per month
• Other telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

How it works:

1. Patient completes a telehealth consultation with a licensed provider
2. Provider writes a prescription for compounded semaglutide if clinically appropriate
3. A 503A or 503B compounding pharmacy prepares the medication
4. Medication ships directly to the patient
5. Patient self-administers using a U-100 insulin syringe (not a pre-filled pen)

Key differences from brand-name Wegovy:

• Compounded semaglutide is not FDA-approved
• It's prepared in response to an individual prescription under state pharmacy law
• It's drawn from a vial, not a pre-loaded pen
• Dosing is flexible (providers can titrate in smaller increments)
• Cost is predictable and not insurance-dependent

When compounded makes sense for Medicare patients:

• Your Part D plan doesn't cover Wegovy
• You don't have diabetes (so Ozempic isn't an option)
• You can't afford $1,350+ monthly out-of-pocket
• You're comfortable with a non-FDA-approved compounded medication
• You're willing to use a syringe instead of a pen

When to pursue other pathways first:

• You have type 2 diabetes and could get Ozempic covered
• You qualify for Medicaid and your state covers Wegovy
• You're willing to switch to a Medicare Advantage plan with supplemental obesity coverage
• You have financial resources to pay cash for brand-name Wegovy

The clinical outcomes with compounded semaglutide appear comparable to brand-name in real-world use, but head-to-head trials don't exist because compounded medications aren't studied in large RCTs. The decision is primarily financial and preference-based.

What changes if the Medicare weight-loss exclusion is repealed

The Treat and Reduce Obesity Act (TROA) has been introduced in Congress multiple times since 2012. The 2025 version (H.R. 1396 / S. 596) would remove the Medicare Part D exclusion for obesity medications, allowing coverage when prescribed for chronic weight management.

If TROA passes:

• Medicare Part D plans would be required to cover FDA-approved obesity medications, including Wegovy, Zepbound, Saxenda, and Qsymia
• Coverage would follow the same formulary and prior authorization rules as other Part D drugs
• Patients would pay standard copays (likely specialty tier: $200 to $500 per month)
• CMS estimates this would add approximately $25 billion to Medicare spending over 10 years (CBO score from 2024 version)

Likelihood of passage: TROA has bipartisan support but faces budget opposition. The 2024 version had 60+ cosponsors in the House and 15+ in the Senate but didn't reach a floor vote. The 2026 budget reconciliation process could include it as a pay-for offset against other health spending, but this is speculative.

What to do now: Don't wait for legislative change. TROA has been "likely to pass soon" since 2015. If you need Wegovy now, pursue the pathways that exist today: Medicare Advantage supplemental coverage, compounded alternatives, or Ozempic if diabetic.

The political tension no one talks about: Medicare coverage of obesity drugs would reduce long-term costs (fewer heart attacks, strokes, diabetes complications) but increase short-term spending (drug costs). CMS operates on annual budgets. The savings accrue over 10-20 years. The costs hit immediately. This mismatch makes TROA politically difficult despite strong clinical evidence. The same dynamic delayed Medicare Part D coverage of diabetes prevention programs for 8 years after clinical trials proved cost-effectiveness.

How to verify your specific Medicare Advantage plan's coverage

Step 1: Find your plan's formulary. Every Medicare Advantage plan publishes a formulary (list of covered drugs). It's available on the plan's website or by calling the member services number on your card. Search for "semaglutide" and "Wegovy."

Step 2: Check the tier and restrictions. If Wegovy appears on the formulary, note the tier (usually 4 or 5, specialty). Look for "PA" (prior authorization required), "QL" (quantity limit), or "ST" (step therapy required). These restrictions determine whether you can access it.

Step 3: Call and ask specific questions.

• "Is Wegovy covered for chronic weight management, or only for diabetes?"
• "What is the copay or coinsurance for a 30-day supply?"
• "What are the prior authorization requirements?"
• "Is there a BMI threshold or comorbidity requirement?"
• "Do I need to participate in a weight-management program to qualify?"

Step 4: Get the answer in writing. Ask the representative to send you a summary of benefits document or email confirmation. Verbal answers are sometimes wrong. Written documentation protects you if the plan denies coverage later.

Step 5: Compare plans during open enrollment. If your current plan doesn't cover Wegovy, compare other Medicare Advantage plans in your area during the annual open enrollment period (October 15 to December 7). Use Medicare.gov's plan finder tool and filter for plans that cover obesity medications.

The verification process takes 30-60 minutes. It prevents the common scenario where a patient starts Wegovy, assumes Medicare will cover it, and receives a $1,430 bill at the pharmacy.

The decision tree: four pathways for Medicare patients who need Wegovy

If you have type 2 diabetes: → Check if your Part D plan covers Ozempic for diabetes → If yes: pursue Ozempic (up to 2 mg weekly), expect $200-500/month copay → If no: consider compounded semaglutide or switch plans during open enrollment

If you don't have diabetes but qualify for Medicaid (dual-eligible): → Check your state Medicaid formulary for Wegovy coverage → If your state covers it: work with your provider to submit prior authorization → If your state doesn't cover it: pursue compounded semaglutide or Medicare Advantage supplemental

If you're on Medicare Advantage: → Check if your plan offers supplemental obesity-drug coverage → If yes: enroll in the rider (if optional) and follow PA process → If no: compare other Medicare Advantage plans during open enrollment or pursue compounded semaglutide

If you're on Original Medicare Part D with no other coverage: → Wegovy is not covered, no pathway to coverage under current law → Options: (1) pay cash ($1,350+/month), (2) switch to Medicare Advantage with supplemental coverage, (3) pursue compounded semaglutide ($179-350/month)

FAQ

Does Medicare cover Wegovy for weight loss? No. Medicare Part D does not cover Wegovy or any medication prescribed solely for weight loss due to a statutory exclusion in the 2003 Medicare Modernization Act. Some Medicare Advantage plans offer supplemental obesity-drug coverage as an optional benefit.

Does Medicare cover Ozempic for weight loss? No. Medicare covers Ozempic only when prescribed for type 2 diabetes. If your provider writes Ozempic for weight management without a diabetes diagnosis, Medicare will deny coverage. Some patients with both diabetes and obesity receive Ozempic for diabetes and experience weight loss as a secondary benefit.

Can I use the Wegovy savings card if I have Medicare? No. Federal anti-kickback laws prohibit pharmaceutical manufacturers from offering copay assistance to Medicare, Medicaid, TRICARE, or VA beneficiaries. The Novo Nordisk Wegovy savings card explicitly excludes all government-program enrollees.

Which Medicare Advantage plans cover Wegovy? Approximately 15-20% of Medicare Advantage plans offer some form of weight-loss drug coverage as of 2026. UnitedHealthcare, Humana, and Aetna have been most active in adding this benefit. Coverage varies by region and plan. Check your specific plan's formulary or call member services.

How much does Wegovy cost for Medicare patients without coverage? Cash price ranges from $1,350 to $1,700 per month at retail pharmacies. GoodRx coupons can reduce this to $1,300 to $1,550. Compounded semaglutide alternatives cost $179 to $350 per month through telehealth platforms.

Will Medicare ever cover Wegovy? Possibly. The Treat and Reduce Obesity Act (TROA) would remove the Medicare weight-loss drug exclusion if passed. The bill has been introduced multiple times since 2012 but hasn't become law. Timing of potential passage is uncertain.

Does Medicaid cover Wegovy if I have both Medicare and Medicaid? It depends on your state. As of 2026, five states (North Carolina, Louisiana, Vermont, Minnesota, Washington) cover Wegovy for obesity through Medicaid. Most states don't. Dual-eligible patients should check their state Medicaid formulary.

Can I get Wegovy through the VA if I'm also on Medicare? The VA has its own formulary independent of Medicare. Some VA facilities cover Wegovy for veterans with obesity and cardiovascular risk factors. Coverage varies by facility. Contact your VA pharmacy to check availability.

Is compounded semaglutide safe for Medicare patients? Compounded semaglutide prepared by a licensed 503A or 503B pharmacy following USP standards has the same active ingredient as Wegovy. It's not FDA-approved, so it hasn't undergone the same review process. Many Medicare-age patients use compounded semaglutide when brand-name isn't accessible.

What's the difference between Wegovy 2.4 mg and Ozempic 2 mg for weight loss? Clinical trials show approximately 1-2% additional total body weight loss with Wegovy 2.4 mg compared to 2 mg semaglutide. For a 200-pound patient, this translates to roughly 2-4 additional pounds lost. The difference is statistically significant but clinically modest for most patients.

Can I switch from Wegovy to compounded semaglutide without losing progress? Yes. The active ingredient is identical. Patients switching from brand-name to compounded at the same dose typically maintain their weight loss and continue progressing. The main adjustment is switching from a pre-filled pen to drawing from a vial with a syringe.

Do I need prior authorization for Wegovy on Medicare Advantage plans that cover it? Usually yes. Most Medicare Advantage plans that offer Wegovy coverage require prior authorization demonstrating BMI threshold (typically ≥30 with comorbidity or ≥27 with multiple comorbidities), documented lifestyle intervention, and absence of contraindications. Approval takes 3-14 days.

Sources

1. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. CMS.gov. 2024.

1. Social Security Act, Title XVIII, Section 1860D-2(e)(2)(A). Exclusions from Part D Coverage. 2003.

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.

1. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.

1. Congressional Budget Office. Cost Estimate: Treat and Reduce Obesity Act of 2024 (H.R. 1396). CBO.gov. 2024.

1. Kaiser Family Foundation. Medicare Advantage Supplemental Benefits for Chronically Ill Enrollees. KFF.org. 2025.

1. National Council on Aging. State Medicaid Coverage of Anti-Obesity Medications: 2026 Survey. NCOA.org. 2026.

1. Novo Nordisk. Wegovy Prescribing Information. NovoNordisk.com. 2024.

1. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determination and Appeals Guidance. CMS.gov. 2025.

1. American Medical Association. Recognition of Obesity as a Disease: H-440.842. AMA-assn.org. 2013.

1. Office of Inspector General, Department of Health and Human Services. Compliance Program Guidance for Pharmaceutical Manufacturers. Federal Register. 2003.

1. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.

1. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

1. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Rybelsus, and Saxenda are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Medicare and Medicaid are federal programs administered by the Centers for Medicare & Medicaid Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.